A study found that adolescents with maternal incarceration histories were significantly more likely to experience sleep difficulties, along with poorer diet and exercise habits.
Category: Sleep Maintenance Insomnia
Somnus Therapeutics Inc, a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon. The study (SOM201), conducted in nonelderly adults with primary insomnia chRead More
After a long and financially consuming process for Somaxon Pharmaceuticals, the US Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized bRead More
Transcept is anticipating further feedback from the FDA with regard to the activities necessary to resubmit the new drug application (NDA) for its middle-of-the-night insomnia treatment, Intermezzo. With cash, cash equivalents, and marketablRead More
Intra-Cellular Therapies Inc, New York, released final results from the Phase II trial of ITI-007 in patients with sleep maintenance insomnia. The trial showed ITI-007 significantly and dose-dependently increased slow wave sleep and decreased the dRead More
It is important to determine the consequences of age-related changes in all aspects of life in order to develop new strategies to help older individuals cope with sleep-wake cycle regularity challenges.Read More